Telemetry Investments’s Arbutus Biopharma ABUS Stock Holding History

Telemetry Investments’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-45,000	Closed	-$225K	–	129
2018 Q1	$225K	Sell	45,000 -74,497	-62%	-$394K	0.08%	115
2017 Q4	$603K	Buy	119,497 +9,497	+9%	+$55.7K	0.23%	67
2017 Q3	$682K	Sell	110,000 -108,400	-50%	-$464K	0.24%	60
2017 Q2	$786K	Sell	218,400 -6,600	-3%	-$22.7K	0.37%	53
2017 Q1	$731K	Buy	225,000 +75,000	+50%	+$208K	0.33%	48
2016 Q4	$368K	Buy	+150,000	New	+$436K	0.21%	62
2016 Q1	–	Sell	-101,000	Closed	-$449K	–	103
2015 Q4	$449K	Buy	101,000 +38,640	+62%	+$212K	0.15%	82
2015 Q3	$380K	Buy	62,360 +5,860	+10%	+$52K	0.16%	91
2015 Q2	$670K	Buy	56,500 +8,500	+18%	+$129K	0.3%	67
2015 Q1	$838K	Buy	48,000 +12,500	+35%	+$256K	0.46%	43
2014 Q4	$538K	Buy	+35,500	New	+$613K	0.33%	73

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Telemetry Investments's ABUS Position: Q2 2018 in Review

Telemetry Investments sold out of Arbutus Biopharma (ABUS) in Q2 2018, closing a stake of 45,000 shares — an estimated $225K sold.

Telemetry Investments first reported a position in ABUS in Q4 2014 and held it in 11 quarters. The position peaked at $838K in Q1 2015. 71 funds tracked by Wall St. Rank hold ABUS as of Q2 2018.

Telemetry Investments reported no remaining Arbutus Biopharma position as of Q2 2018 after selling out during the quarter.
Telemetry Investments sold 45,000 Arbutus Biopharma shares in Q2 2018, an estimated $225K.
Telemetry Investments first reported a position in Arbutus Biopharma in Q4 2014 and held it in 11 quarters.
Telemetry Investments's Arbutus Biopharma position peaked at $838K in Q1 2015.
71 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2018.

Based on Telemetry Investments's 13F filing for Q2 2018, filed 14 Aug 2018.